Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cheap water pills protect hearts in early kidney disease?

NCT ID NCT05171686

Knowledge-focused Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 21, 2026 · Updated 2 times

Summary

This completed study in 49 veterans with early chronic kidney disease (CKD) tested whether diuretics (water pills) can reduce fluid overload and improve heart health. Researchers measured changes in heart stress markers and symptoms like fatigue after 4 weeks of treatment. The goal was to lay groundwork for future studies on whether early use of these inexpensive drugs can prevent heart problems in CKD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
diuretics (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, bumetanide)
What this could lead to
If successful, this study could show that measuring fluid overload and treating it with diuretics early in kidney disease may improve heart health and symptoms.
What could go wrong
This is a small, early-phase study with only 49 participants, so results may not apply to everyone. It focuses on short-term changes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

49 people

The number who actually took part.

Started

Feb 2023

Finished

Oct 2025

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female Veterans age 18 years or older. There will be no upper age limit. * The presence of CKD stages 1, 2, or 3, as defined below by Kidney Disease Improving Global Outcomes guidelines, for a period of at least 3 months. * Stage 1: eGFR 90 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g. * Stage 2: eGFR 60-89 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g. * Stage 3: eGFR 30-59 mL/min/1.73 m2. * Measured blood pressure either \>140 mmHg systolic or \>90 mmHg diastolic at the two most recent clinic visits. * Able to understand and sign informed consent after the nature of the study has been fully explained. Exclusion Criteria: * Unable to understand or provide informed consent. * Unwilling or unable to participate in the protocol or comply with any of its components. * CKD stages 4-5, defined as eGFR \<30 mL/min/1.73 m2. * Receiving chronic hemodialysis or peritoneal dialysis. * Recipient of a kidney transplant. * Serum potassium \<3.5 mEq/L at baseline. * Known left ventricular ejection fraction \<40% on visual estimate based on chart review of available echocardiogram data. * Known hepatic cirrhosis. * Major limb amputation. * Known pregnancy. * Presence of a pacemaker or defibrillator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease Hypertension

Contacts and locations

Locations

  • Michael E. DeBakey VA Medical Center, Houston, TX

    Houston, Texas, 77030-4211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.